{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=55",
    "query": {
      "intervention": "Formulation #1",
      "page": 55
    },
    "page_size": 10
  },
  "pagination": {
    "page": 55,
    "page_size": 10,
    "total_count": 1760,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=56&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=54&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T00:20:54.616Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00262041",
      "title": "Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prevention of Meningococcal Disease"
      ],
      "interventions": [
        {
          "name": "MenACWY-CRM conjugate vaccine, adjuvanted",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MenACWY-CRM conjugate vaccine, unadjuvanted",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MenACWY polysaccharide vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "11 Years to 17 Years"
      },
      "enrollment_count": 524,
      "start_date": "2004-10",
      "completion_date": "2006-03",
      "has_results": true,
      "last_update_posted_date": "2018-06-28",
      "last_synced_at": "2026-11-08T00:20:54.616Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00262041"
    },
    {
      "nct_id": "NCT07116031",
      "title": "A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Belumosudil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 37,
      "start_date": "2025-12-02",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-11-08T00:20:54.616Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07116031"
    },
    {
      "nct_id": "NCT02010567",
      "title": "Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "CRLX101",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2013-12",
      "completion_date": "2019-06-25",
      "has_results": true,
      "last_update_posted_date": "2020-11-03",
      "last_synced_at": "2026-11-08T00:20:54.616Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Indianapolis, Indiana • Chapel Hill, North Carolina + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02010567"
    },
    {
      "nct_id": "NCT02565173",
      "title": "Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Open-Angle Glaucoma (POAG)",
        "Ocular Hypertension (OHT)"
      ],
      "interventions": [
        {
          "name": "trabodenoson 4.5% BID",
          "type": "DRUG"
        },
        {
          "name": "trabodenoson 6.0% QD",
          "type": "DRUG"
        },
        {
          "name": "trabodenoson 3.0% QD",
          "type": "DRUG"
        },
        {
          "name": "timolol 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "placebo BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 303,
      "start_date": "2015-09",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2016-12-06",
      "last_synced_at": "2026-11-08T00:20:54.616Z",
      "location_count": 1,
      "location_summary": "Lexington, Massachusetts",
      "locations": [
        {
          "city": "Lexington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02565173"
    },
    {
      "nct_id": "NCT00635622",
      "title": "Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bacterial Vaginosis"
      ],
      "interventions": [
        {
          "name": "LACTIN-V",
          "type": "DRUG"
        },
        {
          "name": "Placebo control substance",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Osel, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2008-04",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2009-07-10",
      "last_synced_at": "2026-11-08T00:20:54.616Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00635622"
    },
    {
      "nct_id": "NCT02610777",
      "title": "An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Leukemia, Myelomonocytic, Chronic",
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Pevonedistat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2016-04-14",
      "completion_date": "2021-07-23",
      "has_results": true,
      "last_update_posted_date": "2022-09-19",
      "last_synced_at": "2026-11-08T00:20:54.616Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02610777"
    },
    {
      "nct_id": "NCT04521231",
      "title": "A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B Cell Precursor Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 181,
      "start_date": "2021-01-04",
      "completion_date": "2029-05-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-11-08T00:20:54.616Z",
      "location_count": 13,
      "location_summary": "Clovis, California • Duarte, California • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04521231"
    },
    {
      "nct_id": "NCT04138056",
      "title": "A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3 formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSVPreF3 formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Boostrix-ex-US",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Boostrix-US",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 509,
      "start_date": "2019-11-05",
      "completion_date": "2021-11-22",
      "has_results": true,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-11-08T00:20:54.616Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Lenexa, Kansas • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04138056"
    },
    {
      "nct_id": "NCT03636906",
      "title": "Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV (GSK3389245A) lower dose formulation vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV (GSK3389245A) higher dose formulation vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK's multicomponent meningococcal B vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK's pneumococcal polysaccharide conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK's meningococcal group A, C, W-135 and Y conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "7 Months",
        "sex": "ALL",
        "summary": "6 Months to 7 Months"
      },
      "enrollment_count": 201,
      "start_date": "2019-04-08",
      "completion_date": "2021-07-22",
      "has_results": true,
      "last_update_posted_date": "2022-07-27",
      "last_synced_at": "2026-11-08T00:20:54.616Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Nampa",
          "state": "Idaho"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03636906"
    },
    {
      "nct_id": "NCT04083716",
      "title": "A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "ABI-H2158 Reference Formulation",
          "type": "DRUG"
        },
        {
          "name": "ABI-H2158 Test Formulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Assembly Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2019-09-06",
      "completion_date": "2019-10-07",
      "has_results": false,
      "last_update_posted_date": "2019-11-29",
      "last_synced_at": "2026-11-08T00:20:54.616Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04083716"
    }
  ]
}